Benzoic Acid
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
Benzoic Acid: From Preservative/Antifungal Agent to Pemphigus
One-Sentence Summary
Benzoic acid is a simple aromatic carboxylic acid commonly used as a preservative and topical antifungal agent in pharmaceutical and food products. The TxGNN model predicts it may be effective for Pemphigus, but there are currently no clinical trials and no publications supporting this direction. All five predicted indications lack mechanistic rationale and clinical evidence, making this a very early-stage, model-only prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Preservative and topical antifungal (commonly in combination products) |
| Predicted New Indication | Pemphigus |
| TxGNN Prediction Score | 0.00% |
| Evidence Level | L5 (Model prediction only, no actual studies) |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 36 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Benzoic acid is a widely used preservative and, in combination with salicylic acid (Whitfield’s ointment), serves as a topical antifungal agent. It is primarily recognized for its antimicrobial properties through acidification and disruption of microbial cell membranes, rather than any immunomodulatory or systemic therapeutic activity.
Pemphigus is a group of severe autoimmune blistering diseases driven by autoantibodies (primarily anti-desmoglein 1 and 3) that attack desmosomal adhesion proteins in the skin and mucous membranes. Treatment typically requires systemic immunosuppression with corticosteroids, rituximab, or other immunosuppressive agents. There is no known pharmacological mechanism by which benzoic acid could modulate autoantibody production, complement activation, or desmosomal integrity.
The TxGNN prediction score of 0.00% further underscores the weakness of this association. The model may have identified a structural or graph-based proximity in the knowledge graph, but no biological, clinical, or mechanistic evidence supports the repurposing of benzoic acid for pemphigus or any of the other four predicted indications (dermatomyositis, systemic sclerosis, balanitis xerotica obliterans, penile fibromatosis).
Clinical Trial Evidence
Currently no related clinical trials registered for any of the five predicted indications.
Literature Evidence (Systemic Sclerosis — Rank 3)
No literature was identified for the top-ranked prediction (pemphigus) or for dermatomyositis, balanitis xerotica obliterans, or penile fibromatosis. Four publications were retrieved for the rank-3 indication (systemic sclerosis), but none demonstrate direct relevance to benzoic acid as a therapeutic agent for systemic sclerosis:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33118131 | 2021 | Preclinical/Animal | Neurotherapeutics | A nitroalkene benzoic acid derivative (not benzoic acid itself) showed NF-κB inhibition in an ALS mouse model — unrelated to systemic sclerosis |
| 33331912 | 2021 | Basic Science (in vitro) | Rheumatology | Investigated CLIC4 in SSc fibroblast activation — no mention of benzoic acid as therapeutic agent |
| 33078092 | 2020 | Medicinal Chemistry | Acta Pharm Sin B | DHODH inhibitors (acrylamidobenzoic acid analogs) for rheumatoid arthritis — synthetic derivatives, not benzoic acid |
| 9462746 | 1998 | Basic Science (knockout mouse) | Nat Genet | MnSOD knockout mouse neurological phenotype — no connection to benzoic acid or systemic sclerosis |
Note: All four publications are keyword mismatches — they mention benzoic acid derivatives or unrelated disease contexts. None provide evidence supporting benzoic acid for systemic sclerosis treatment.
Malaysia Market Information
Benzoic acid is registered with 36 product licences in Malaysia. However, detailed licence information (authorization numbers, product names, dosage forms, and approved indications) was not available in the current data extraction.
| Item | Content |
|---|---|
| Total Registrations | 36 |
| Product Details | Not available in current dataset |
Benzoic acid is typically registered as an excipient/preservative or in combination topical antifungal products (e.g., Whitfield’s ointment with salicylic acid).
Safety Considerations
Please refer to the package insert for safety information. Key warnings, contraindications, and drug interaction data were not available in this evidence pack. No drug-drug interactions were identified in the DrugBank query.
Conclusion and Next Steps
Decision: Hold
Rationale: All five TxGNN-predicted indications for benzoic acid scored 0.00% and carry an L5 evidence level (model prediction only). There are no clinical trials, no relevant publications, and no mechanistic rationale linking benzoic acid — a simple preservative/topical antifungal — to any of the predicted autoimmune or fibrotic conditions (pemphigus, dermatomyositis, systemic sclerosis, balanitis xerotica obliterans, penile fibromatosis). The four retrieved publications for systemic sclerosis are all keyword mismatches involving unrelated benzoic acid derivatives or disease models.
To proceed, the following would be needed:
- Identification of a plausible mechanism of action linking benzoic acid to autoimmune or fibrotic pathways
- At least preclinical evidence (in vitro or animal model) demonstrating therapeutic effect of benzoic acid (not derivatives) in any of the predicted indications
- Completion of safety profile data (package insert warnings, contraindications)
- Clarification of route compatibility — current registered forms are predominantly topical/preservative, whereas the predicted indications would likely require systemic therapy
Disclaimer: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.